Combination of Chemotherapy and Monoclonal Antibodies for the Treatment of Lymphoma

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Monoclonal antibodies (MoAbs) have transformed the treatment of lymphomas. The first reports of studies using MoAbs appeared 8 years ago, and current therapy for lymphoma patients usually includes treatment with MoAbs once or several times during the course of their disease. This review covers the use of MoAbs in combination with chemotherapy for the treatment of patients with lymphoma. Rituximab, an unconjugated anti-CD20 chimeric antibody, is certainly the most widely used MoAb, but the use of other unconjugated or radiolabeled MoAbs is increasing quickly. MoAbs are effective if used alone, but the duration of effectiveness is limited. Therefore, when MoAbs are used in curative treatment, they are combined with chemotherapy. There are randomized studies demonstrating the benefit of adding MoAbs to the treatment regimen of patients with diffuse large B-cell lymphoma, but results of ongoing studies regarding the benefit in other lymphomas have not been reported. Many questions must be answered before the best setting for MoAbs in the treatment of lymphoma patients can be determined. Int J Hematol. 2002;76:394-400.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.Semin Oncol. 1999;26:66–73.

    PubMed  CAS  Google Scholar 

  2. 2.

    Grossbard ML, Fidias P, Kinsella J, et al. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.Brit J Haematol. 1998;102:509–515.

    Article  CAS  Google Scholar 

  3. 3.

    Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131 - Anti-B1 radioimmunotherapy for B-cell lymphoma.J Clin Oncol. 1996;14: 1974–1981.

    Article  PubMed  CAS  Google Scholar 

  4. 4.

    Witzig TE,White CA,Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 1999;17: 3793–3803.

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457–2466.

    PubMed  CAS  Google Scholar 

  6. 6.

    Maloney DG, Grillolopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed nonHodgkin’s lymphoma.J Clin Oncol. 1997;15:3266–3274.

    Article  PubMed  CAS  Google Scholar 

  7. 7.

    Foran JM, Rohatiner AZS, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma.J Clin Oncol. 1999;17:546–553.

    Article  PubMed  CAS  Google Scholar 

  8. 8.

    Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study.Blood. 1998;92:1927–1932.

    PubMed  CAS  Google Scholar 

  9. 9.

    Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (Idec-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.Cancer Chemother Pharmacol. 1997;12:177–186.

    CAS  Google Scholar 

  10. 10.

    Shan D, Ledbetter JA, Press OW.Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.Blood. 1998; 91:1644–1652.

    PubMed  CAS  Google Scholar 

  11. 11.

    Shan DM, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.Cancer Immunol Immunother. 2000;48:673–683.

    Article  PubMed  CAS  Google Scholar 

  12. 12.

    Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B- lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin.Blood. 2001;97:1392–1398.

    Article  PubMed  CAS  Google Scholar 

  13. 13.

    Alas S, Bonavida B.Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/ paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.Cancer Res. 2001;61:5137–5144.

    PubMed  CAS  Google Scholar 

  14. 14.

    Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.N Engl J Med. 2001;345:241–247.

    Article  PubMed  CAS  Google Scholar 

  15. 15.

    Dearden CE, Matutes E, Cazin B, et al. High remission rate in T- cell prolymphocytic leukemia with CAMPATH-1H.Blood. 2001; 98:1721–1726.

    Article  PubMed  CAS  Google Scholar 

  16. 16.

    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833.

    Article  PubMed  CAS  Google Scholar 

  17. 17.

    Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas.J Clin Oncol. 2001;19:3918–3928.

    Article  PubMed  CAS  Google Scholar 

  18. 18.

    Gordon LI,Witzig TE, Emmanouilides CE, et al. 90Y ibritumomab (Zevalin) in aggressive non-Hodgkin’s lymphoma: analysis of response and toxicity [review].Semin Oncol. 2002;29(suppl 2): 87–92.

    Article  PubMed  CAS  Google Scholar 

  19. 19.

    Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 2002;20:2453–2463.

    Article  PubMed  CAS  Google Scholar 

  20. 20.

    Foran JM, Rohatiner AZS, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.J Clin Oncol. 2000;18:317–324.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. 21.

    Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.Ann Oncol. 2000;11:117–121.

    Article  PubMed  Google Scholar 

  22. 22.

    The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage.Cancer. 1982;49:2112–2135.

    Article  Google Scholar 

  23. 23.

    Pan D, Moskowitz CH, Zelenetz AD, Teruya-Feldstein J, Portlock CS. Clinical outcomes of patients treated with rituximab for relapsed or refractory aggressive non-Hodgkin’s lymphoma in the post-transplant setting [abstract].Blood. 2000;96(suppl 1):405a. Abstract 1746.

    Google Scholar 

  24. 24.

    Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol. 1999;17:268–276.

    Article  PubMed  CAS  Google Scholar 

  25. 25.

    Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.Semin Oncol. 2002;29:36–40.

    Article  PubMed  CAS  Google Scholar 

  26. 26.

    Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.J Clin Oncol. 2002;20:1288–1294.

    Article  PubMed  CAS  Google Scholar 

  27. 27.

    Romaguera JE, Dang NH, Hagemeister FB, et al. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL).Blood. 2000;96:733a.

    Google Scholar 

  28. 28.

    Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma.J Clin Oncol. 2001;19:389–397.

    Article  PubMed  CAS  Google Scholar 

  29. 29.

    Kewalramani T, Zelenetz A, Bertino J, et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as secondline therapy (SLT) [abstract].Blood. 2001;98(suppl 1):346a. Abstract 1458.

    Google Scholar 

  30. 30.

    Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.N Engl J Med. 2002;346:235–242.

    Article  PubMed  CAS  Google Scholar 

  31. 31.

    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma.N Engl J Med. 1993;329:987–994.

    Article  Google Scholar 

  32. 32.

    Hiddemann W, Forstpointner R, Fiedler F, et al. The addition of rituximab to combination chemotherapy with fludarabine, cyclophosphamide, mitoxantrone (FCM) results in a significant increase of overall response as compared to FCM alone in patients with relapsed or refractory follicular (FCL) and mantel cell lymphomas (MCL). Results of a prospective randomized comparison of the German low grade study group (GLSG) [abstract].Blood. 2001; 98(suppl 1):844a. Abstract 3507.

    Google Scholar 

  33. 33.

    Ghielmini M, Schmite SFH, Cogliatti SB, et al. Maintenance treatment with 2-monthly rituximab after standard weekly X4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma.Ann Oncol. 2002;13(suppl 2):38.

    Google Scholar 

  34. 34.

    Leonard JP, Coleman M, Matthews JC, et al. Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin’s lymphoma: preliminary response data [abstract].Blood. 2000;96(suppl 1):578a. Abstract 2482.

    Google Scholar 

  35. 35.

    Witzig TE,White CA,Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 1999;17: 3793–3803.

    Article  PubMed  CAS  Google Scholar 

  36. 36.

    Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.Lancet. 1995;346:336–340.

    Article  PubMed  CAS  Google Scholar 

  37. 37.

    Coiffier B. Diffuse large-cell lymphoma.Curr Op Oncol. 2001;13: 325–334.

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Catherine Thieblemont or Bertrand Coiffier.

About this article

Cite this article

Thieblemont, C., Coiffier, B. Combination of Chemotherapy and Monoclonal Antibodies for the Treatment of Lymphoma. Int J Hematol 76, 394–400 (2002). https://doi.org/10.1007/BF02982804

Download citation

Key words

  • Chemotherapy
  • Diffuse large cell lymphoma
  • Rituximab